2015
The Lifetime Medical Cost Savings From Preventing HIV in the United States
Schackman BR, Fleishman JA, Su AE, Berkowitz BK, Moore RD, Walensky RP, Becker JE, Voss C, Paltiel AD, Weinstein MC, Freedberg KA, Gebo KA, Losina E. The Lifetime Medical Cost Savings From Preventing HIV in the United States. Medical Care 2015, 53: 293-301. PMID: 25710311, PMCID: PMC4359630, DOI: 10.1097/mlr.0000000000000308.Peer-Reviewed Original ResearchConceptsHIV infectionLifetime medical costsMedical costsUS health system perspectiveAntiretroviral treatment statusHIV disease treatmentHIV Research NetworkTransmission risk groupsCD4 cell countHigh-risk individualsHealth system perspectiveHIV prevention interventionsMedical cost savingsMedical Expenditure Panel SurveyLifetime cost estimatesRace/ethnicityPreexposure prophylaxisHIV diseaseHIV preventionRisk groupsPrevention interventionsAge 35High riskSecondary infectionTreatment status
2012
Newer drugs and earlier treatment
Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment. AIDS 2012, 26: 45-56. PMID: 22008655, PMCID: PMC3237010, DOI: 10.1097/qad.0b013e32834dce6e.Peer-Reviewed Original ResearchConceptsCD4 cell countAntiretroviral therapyHIV RNACD4 cellsHIV diseaseCells/Life expectancyCell countMean CD4 cell countMean age 38 yearsAge 38 yearsMedical resource utilizationLifetime costsUndiscounted life expectancyCost of careAIDS Complications (CEPAC) modelART initiationHIV CostRegimen costsAntiretroviral drugsART costsEarly treatmentCopies/High-income countriesEfficacious drugs
2005
Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients
Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. Antiviral Therapy 2005, 10: 41-52. PMID: 15751762, DOI: 10.1177/135965350501000102.Peer-Reviewed Original ResearchConceptsCD4 cell countQuality-adjusted life yearsHIV RNA monitoringAntiretroviral therapy initiationIncremental CE ratioCell countAntiretroviral therapyTherapy initiationTreatment thresholdCD4 cell count thresholdCD4 cells/mm3Initial clinical presentationCells/mm3Log10 copies/Incremental clinical benefitLife expectancyQuality-adjusted life expectancyHIV simulation modelHypothetical clinical settingsMore frequent monitoringCost-effectiveness analysisCell count thresholdAntiretroviral initiationVirological predictorsHIV RNA
2003
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal Of Medicine 2003, 115: 632-641. PMID: 14656616, DOI: 10.1016/j.amjmed.2003.07.007.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHuman immunodeficiency virus (HIV) infectionClinical trial cohortImmunodeficiency virus infectionAdvanced diseaseCost-effectiveness ratioAdherence interventionsAntiretroviral therapyTrial cohortEarly diseaseVirus infectionUrban cohortLife expectancyHIV ribonucleic acid levelsEffective adherence interventionsCD4 cell countCombination antiretroviral therapyVirologic failure ratesLow baseline levelsFailure rateRibonucleic acid levelsStandard careHIV infectionHealthy patientsClinical trials
2002
Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy
Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. Antiviral Therapy 2002, 7: 257-266. PMID: 12553480, DOI: 10.1177/135965350200700405.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyHIV infectionCD4 strataAntiretroviral therapyHIV careHIV diseaseLifetime costsHighly Active Antiretroviral TherapyHigher CD4 strataHIV Clinical CohortLowest CD4 stratumCD4 cell countEra of HAARTBurden of diseaseStage of illnessCost of careHealth policy plannersHealth care costsClinical managementSpecific AIDSClinical cohortMean costFrench patientsCare costsCell countProphylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. JAMA Internal Medicine 2002, 162: 921-928. PMID: 11966344, DOI: 10.1001/archinte.162.8.921.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-Infective AgentsAntiprotozoal AgentsAtovaquoneCD4 Lymphocyte CountCost-Benefit AnalysisDapsoneDrug CostsHumansLife ExpectancyModels, TheoreticalNaphthoquinonesPentamidinePneumonia, PneumocystisPractice Guidelines as TopicQuality-Adjusted Life YearsConceptsQuality-adjusted life yearsCD4 cell countQuality-adjusted life expectancyPneumocystis carinii pneumoniaCD4 cell count increasePCP prophylaxisCell count increaseCell countCarinii pneumoniaClinical guidelinesCD4 cell count criteriaInitial CD4 cell countCD4 lymphocyte countPrimary PCP prophylaxisActive antiretroviral therapyCohort of HIVHuman immunodeficiency virusTMP/SMXCount increaseAntiretroviral therapyLymphocyte countHIV infectionImmunodeficiency virusTrimethoprim-sulfamethoxazoleProphylaxis
2001
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G, Craven D, Zhang H, Kimmel A, Goldie S. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal Of Medicine 2001, 344: 824-831. PMID: 11248160, DOI: 10.1056/nejm200103153441108.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisDirect Service CostsDisease ProgressionDrug CostsDrug Therapy, CombinationHealth Care CostsHIV InfectionsHumansLife ExpectancyModels, BiologicalQuality-Adjusted Life YearsRNA, ViralUnited StatesValue of LifeConceptsQuality-adjusted yearThree-drug therapyCombination antiretroviral therapyCD4 cell countQuality of lifeAntiretroviral therapyHIV diseaseClinical benefitDrug costsLife expectancyCell countInitial CD4 cell countThree-drug antiretroviral regimensHuman immunodeficiency virus (HIV) infectionHIV RNA levelsPerson lifetime costsImmunodeficiency virus infectionMajor clinical trialsDirect medical costsStandard of careProgression of diseaseLifetime direct medical costsCost-effectiveness ratioServices Utilization SurveyCost effectiveness
1998
The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections
Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD. The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. JAMA 1998, 279: 130-136. PMID: 9440663, DOI: 10.1001/jama.279.2.130.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAnti-Infective AgentsCD4 Lymphocyte CountChemopreventionCost-Benefit AnalysisCytomegalovirus InfectionsData CollectionHealth Care CostsHumansLife ExpectancyMarkov ChainsModels, TheoreticalMycobacterium avium-intracellulare InfectionMycosesPneumonia, PneumocystisQuality-Adjusted Life YearsRisk FactorsToxoplasmosisUnited StatesConceptsPneumocystis carinii pneumoniaCD4 cell countQuality-adjusted life expectancyOpportunistic infectionsCell countLife expectancyAdvanced human immunodeficiency virus diseaseAverage total lifetime costsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex infectionMulticenter AIDS Cohort StudyIncremental cost-effectiveness ratioHIV patient careCost of prophylaxisCost-effective prophylaxisDirect medical costsAIDS Cohort StudyLifetime direct medical costsLong-term survivalCost-effectiveness ratioServices Utilization SurveyMarkov simulation modelTotal lifetime costsCytomegalovirus diseasePreventing AIDS